Showing results (31-40 of 172) with videos related to
Sort By:
Pageof 18
Journal of Biopharmaceutical Statistics|April 23, 2009
Optimal cost-effective designs of Phase II proof of concept trials and associated go-no go decisionsCong Chen, Robert A BeckmanBiotechniques|October 21, 2005
Pharmacogenetics and pharmacogenomics in oncology therapeutic antibody developmentLi Yan, Robert A BeckmanAdvances in Experimental Medicine and Biology|November 5, 2015
Efficient, Adaptive Clinical Validation of Predictive Biomarkers in Cancer Therapeutic DevelopmentRobert A Beckman, Cong ChenBiomarkers in Medicine|September 3, 2015
Translating predictive biomarkers within oncology clinical development programsRobert A Beckman, Cong ChenClinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 15, 2014
Maximizing return on socioeconomic investment in phase II proof-of-concept trialsCong Chen, Robert A BeckmanBiotechniques|February 25, 2005
Incorporation of reporter-labeled nucleotides by DNA polymerasesJon P Anderson, Bernhard Angerer, Lawrence A LoebProceedings of the National Academy of Sciences of the United States of America|June 16, 2004
Protein tolerance to random amino acid changeHaiwei H Guo, Juno Choe, Lawrence A LoebProceedings of the National Academy of Sciences of the United States of America|January 19, 2010
Optimization of DNA polymerase mutation rates during bacterial evolutionErn Loh, Jesse J Salk, Lawrence A LoebPlos One|January 25, 2012
The Werner syndrome protein is distinguished from the Bloom syndrome protein by its capacity to tightly bind diverse DNA structuresAshwini Kamath-Loeb, Lawrence A Loeb, Michael FryThe Journal of Biological Chemistry|July 31, 2002
Distribution of mutations in human thymidylate synthase yielding resistance to 5-fluorodeoxyuridineHisaya Kawate, Daniel M Landis, Lawrence A LoebPageof 18